Ovarian Cancer

CMS approves changes allowing limited utilization management in protected classes of drugs. However, other proposed changes that would have further eroded patient access were not implemented. Read More ›

A bipartisan bill designed to remove disparity in pricing between intravenously administered drugs and orally administered drugs for patients with cancer was passed in the House in March 2019 but awaits action in the Senate. Read More ›

There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes will affect many patients’ out-of-pocket spending for anticancer drugs, including poly (ADP-ribose) polymerase inhibitors. Read More ›

The ovarian cancer patients’ internal dialogue may delay a cancer diagnosis and can also overestimate the capability of chemotherapy. Read More ›

BRCA wild-type tumors are more common in women with ovarian cancer and may need higher doses of the tumor-targeting PARP inhibitor. Read More ›

The rise in the number of cancer drugs taken orally has placed a renewed focus on the importance—and challenges—of patient adherence to self-administered oral medications. Read More ›

While Medicare Part D enrollees may see their out-of-pocket expenses, deductibles, and premiums increase in 2020, protections of the drugs used in cancer treatment will remain in place. Read More ›

Ovarian cancer not only exacts a high mortality rate, but also affects the physical, mental, and financial health of those diagnosed with the disease. Read More ›

Epidemiologic studies reveal population-based disparities in ovarian cancer morbidity and mortality rates. Read More ›

Genetic, menstrual, and other factors have been associated with increased risk of ovarian cancer. Read More ›